Molecular mechanism of osteolytic bone metastases

Cancer

Volumn 88, Issue 12 SUPPL., 2000, Pages 2892-2898

  Guise, Theresa A ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Bone metastasis; Breast carcinoma; Osteolysis; Parathyroid hormone related protein; Transforming growth factor

Indexed keywords

ESTROGEN RECEPTOR ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE RELATED PROTEIN; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; DNA BINDING PROTEIN; ESTROGEN RECEPTOR; PROTEIN; PTHLH PROTEIN, HUMAN; SMAD2 PROTEIN; SMAD2 PROTEIN, HUMAN; SMAD2 PROTEIN, MOUSE; TRANSACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BONE METASTASIS; BREAST CARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; ANIMAL; BONE TUMOR; BREAST TUMOR; FEMALE; METASTASIS; PATHOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; HUMANS; MICE; OSTEOLYSIS; PARATHYROID HORMONE-RELATED PROTEIN; PROTEINS; RECEPTORS, ESTROGEN; SMAD2 PROTEIN; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0034658725     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000615)88:12+<2892::aid-cncr2>3.0.co;2-y     Document Type: Conference Paper

References (55)

1. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-6.
2. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;1:571-2.
3. Taube T, Elomaa I, Blomqvist C, Beneton MNC, Kanis JA. Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone 1994;15(2):161-6.
4. Boyde A, Maconnachie E, Reid SA, Delling G, Mundy GR. Scanning electron microscopy in bone pathology: review of methods. Potential and applications. Scanning Electron Microsc 1986;IV:1537-54.
5. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996;335(24):1785-91.
6. Bundred NJ, Walker RA, Ratcliffe WA, Warwick J, Morrison JM, Ratcliffe JG. Parathyroid hormone related protein and skeletal morbidity in breast cancer. Eur J Cancer 1992;28(2-3):690-2.
7. Bundred NJ, Ratcliffe WA, Walker RA, Cjoley S, Morrison JM, Ratcliffe JG. Parathyroid hormone related protein and hypercalcaemia in breast cancer. Br Med J 1991;303(6816): 1506-9.
8. Powell GJ, Southby J, Danks JA, Stillwell RG, Hayman JA, Henderson MA, et al. Localization of parathyroid hormone-related protein in breast cancer metastasis: increased incidence in bone compared with other sites. Cancer Res 1991; 51:3059-61.
9. Vargas SJ, Gillespie MT, Powell GJ, Southby J, Danks JA, Moseley JM, et al. Localization of parathyroid hormone-related protein mRNA expression and metastatic lesions by in situ hybridization. J Bone Miner Res 1992;7(8):971-80.
10. Bouizar Z, Spyratos F, Deytieux S, de Vernejoul M, Jullienne A. Polymerase chain reaction analysis of parathyroid hormone-related protein gene expression in breast cancer patients and occurrence of bone metastases. Cancer Res 1993; 53:5076-8.
11. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, et al. Evidence for a causal role of parathyroid hormone-related protein in breast cancer-mediated osteolysis. J Clin Invest 1996;98(7):1544-8.
12. Moseley JM, Kubota M, Diefenbach-Jagger H, Wettenhall REH, Kemp BE, Suva LJ, et al. Parathyroid hormone-related protein purified from a human lung cancer cell line. Proc Natl Acad Sci USA 1987;84:5048-52.
13. Burtis WJ, Wu T, Bunch C, Wysolmerski J, Insogna K, Weir E, et al. Identification of a novel 17,000-Dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy. J Biol Chem 1987;262(15):7151-6.
14. Strewler GJ, Stern P, Jacobs J, Eveloff J, Klein RF, Leung SC, et al. Parathyroid hormone-like protein from human renal carcinoma cells structural and functional homology with parathyroid hormone. J Clin Invest 1987;80:1803-7.
15. Suva LJ, Winslow GA, Wettenhall REH, Hammonds RG, Moseley JM, Dieffenbach-Jagger, et al. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 1987;237:893-6.
16. Abou-Samra A, Juppner H, Force T, Freeman MW, Kong X, Schipani E, et al. Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol triphosphates and increases intracellular free calcium. Proc Natl Acad Sci USA 1992;89:2732-6.
17. Horiuchi N, Caulfield M, Fisher JE, Goldman M, Mckee R, Reagan J, et al. Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro. Science 1987;238:1566-8.
18. Kemp BE, Moseley JM, Rodda CP, Ebeling PR, Wettenhall REH, Stapleton D, et al. Parathyroid hormone-related protein of malignancy: active synthetic fragments. Science 1987; 238:1568-70.
19. Burtis WJ, Bady TF, Orloff JJ, Ersbak, JB, Warrell RP, Olson BR, et al. Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med 1990;322: 1106-12.
20. Southby J, Kissin MW, Danks JA, Hayman JA, Moseley JM, Henderson MA, et al. Immunohistochemical localization of parathyroid hormone-related protein in breast cancer. Cancer Res 1990;50:7710-6.
21. Thomas RJ, Guise TA, Yin JJ, Elliot J, Horwood NJ, Martin TJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999;140:4451-8.
22. Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE, Klagsbrun M. Growth factors in bone matrix. J Biol Chem 1986; 261:12665-74.
23. Pfeilschifter J, Mundy GR. Modulation of transforming growth factor β activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci USA 1987;84:2024-8.
24. Southby J, Murphy LM, Martin TJ, Gillespie MT. Cell-specific and regulator-induced promoter usage and messenger ribonucleic acid splicing for parathyroid hormone-related protein. Endocrinology 1996;137:1349-57.
25. Merryman JI, DeWille JW, Werkmeister JR, Capen CC, Rosol TJ. Effects of transforming growth factor-β on parathyroid hormone-related protein production and ribonucleic acid expression by a squamous carcinoma cell line in vitro. Endocrinology 1994;134:2424-30.
26. Kiriyama T, Gillespie MT, Glatz, JA, Fukumoto S, Moseley JM, Martin TJ. Transforming growth factor β stimulation of parathyroid hormone-related protein (PTHrP): a paracrine regulator? Mol Cellular Endocrinol 1992;92:55-62.
27. Yin JJ, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massgué J, et al. TGF β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999;103:197-206.
28. Massagué J. TGFβ signal transduction. Annu Rev Biochem 1998;67:753-91.
29. Zhang Y, Derynck R. Regulation of Smad signalling by protein associations and signalling crosstalk. Trends Cell Biol 1999;9:274-9.
30. Hahn SA, Schutte M, Shamsul Hoque ATM, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-53.
31. Oft M, Heider KH, Beug H. TGF-β signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 1998; 8(23):1243-52.
32. Welch DR, Fabra A, Nakajima M. Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA 1990;87: 7678-82.
33. Cui WE, Fowlis DJ, Bryson S, Akhurst R. TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 1996; 86:531-42.
34. Wieser R, Attisano L, Wrana JL, Massagué J. Signaling activity of transforming growth factor β type II receptors lacking specific domains in the cytoplasmic region. Mol Cell Biol 1993;13:7239-47.
35. Wieser R, Wrana JL, Massagué J. GS domain mutations that constitutively activate T beta R-I, the downstream signaling component in the TGF-beta receptor complex. EMBO J 1995;14(10):2199-208.
36. Yin JJ, Selander K, Rankin W, Chirgwin JM, Dallas M, Mundy GR, Guise TA. The effects of transforming growth factor-β on breast cancer-mediated osteolysis are mediated by parathyroid hormone-related protein via the Smad signaling pathway. J Bone Miner Res 1999;14(Suppl 1).
37. Hocevar A, Brown TL, Howe PH. TGFβ induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J 1999;18:1345-56.
38. Macias-Silva M, Abdollah S, Hoodless PA, Attisano L, Wrana J. MADR2 is a substrate of the TGFβ receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell 1996;87(7):1215-24.
39. Quinn JM, Elliott J, Gillespie MT, Martin TJ. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998;139:4424-7.
40. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
41. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-602.
42. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998;188:997-1001.
43. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390:175-9.
44. Wong BR, Josien R, Lee SY, Sauter B, Li HL, Steinman RM, et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997;186:2075-80.
45. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997;272:25190-4.
46. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20(3):345-57.
47. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
48. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;139:1329-37.
49. Brunn Rasmussen B, Kamby C. Immunohistochemical detection of estrogen receptors in paraffin sections from primary and metastatic breast cancer. Pathol Res Pract 1989; 185(6):856-9.
50. Henderson MA, Danks JA, Slavin J, Moseley JM, Harris T, Martin TJ. Production of PTHrP by primary breast cancers predicts improved patient survival and decreased bone metastases. J Bone Miner Res 1999;14(Suppl 1):S135,1082A.
51. Thiede MA, Harm SC, Hasson DM, Gardner RM. In vivo regulation of parathyroid hormone-related peptide messenger ribonucleic acid in the rat uterus by 17 β-estradiol. Endocrinology 1991;128:2317-23.
52. Funk JL Wei H. Regulation of PTHrP expression in MCF-7 breast carcinoma cells by estrogen and antiestrogens. Biochem Biophys Res Commun 1998;251:849-54.
53. Zhang Q-X, Borg A, Wolf DM, Oesterreich S, Fuqua SAW. An ER mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res 1997;57:1244-9.
54. Kohler MF, Berkholz A, Risinger JI, Elbendary A, Boyd J, Berchuck A, et al. Mutational analysis of the ER gene in endometrial carcinoma. Obstet Gynecol 1995;86:33-7.
55. Yanagasawa J, Yanagi Y, Masuhiro Y, Suzawa M, Watanabe M, Kashiwagi K, et al. Convergence of TGFβ and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 1999;283:1317-21.